Showing results (321-330 of 351) with videos related to
Sort By:
Pageof 36
Bone Marrow Transplantation|May 7, 2026
Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committeeRoser Velasco, Martin Schmidt-Hieber, Olaf Penack, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLaurent Garderet, Simona Iacobelli, Philippe Moreau, et al.The Lancet. Haematology|July 3, 2025
Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeGandhi Damaj, Ali Bazarbachi, Philipp Berning, et al.Open Forum Infectious Diseases|May 5, 2025
The Changing Impact of Human Cytomegalovirus Serology and Infection on Patient Outcome After Allogeneic Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey in the Era of Letermovir ProphylaxisCorrado Girmenia, Patrizia Chiusolo, Giovanni Marsili, et al.Haematologica|May 4, 2019
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditionsPeter Valent, Attilio Orazi, Michael R Savona, et al.British Journal of Haematology|April 5, 2024
Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMTFrancesco Onida, Luuk Gras, Junran Ge, et al.Blood|January 19, 2017
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panelTheo de Witte, David Bowen, Marie Robin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO NetworkRaphael Itzykson, Valeria Santini, Sylvain Thepot, et al.American Journal of Hematology|November 27, 2023
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMTAlicia Rovó, Luuk Gras, Brian Piepenbroek, et al.The Lancet. Haematology|September 23, 2024
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trialDomenico Russo, Nicola Polverelli, Simona Bernardi, et al.Pageof 36